BENZYL 4-HYDROXY-4-(TRIFLUOROMETHYL)PIPERIDINE-1-CARBOXYLATE, 95.0%, 10g

5,6-Dichloropyridine-3-methanol, 97.0%, 5g

3,5-Dichloro-4-methylbenzoic acid, 95.0%, 5g

[3-(morpholin-4-ylmethyl)phenyl]methanamine, 98%, 5g

tert-butyl 3-(aminomethyl)-3-hydroxy-1-piperidinecarboxylate, 95.0%, 10g

4-Bromo-2-hydroxy-benzaldehyde, 98.0%, 5g

DABRAFENIB MESYLATE, 95%, 100mg

tert-Butanol, min. 99%, for synthesis, 1 l, glass packaging

1,2,2,6,6-Pentamethylpiperidin-4-one, 97%, 5g

GC capillary column ROTI®Cap-1701, 50 m, 0.25 mm, 0.25 µm, 1 Piece(s)

4-(4-Dimethylaminophenylazo)phenylarsonic Acid Hydrochloride>95.0%(T)1g

4,4'-Bis((E)-2-(9-ethyl-9H-carbazol-3-yl)vinyl)-1,1'-biphenyl, 95% mix TBC as stabilizer, 1g

1-Butyl-2,3-dimethylimidazolium Chloride>98.0%(HPLC)(T)5g